AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Mediastinum · 2026-10 · 10 · AB008-AB008
DOI: 10.21037/med-26-ab008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Jordi Remon und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Remon, J., Bironzo, P., Girard, N., Bigay-Game, L., Juan-Vidal, O., Castro, J. D., Reguart, N., Greillier, L., Cousin, S., Dansin, E., Majem, M., Bernabé, R., Martinez, J. M., Díaz, M., Meya, A., Alcalá-López, D., García-Sanz, A., Righi, L., Novello, S., & Besse, B. (2026). AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Mediastinum, 10, AB008-AB008. https://doi.org/10.21037/med-26-ab008
Vancouver
Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, Castro JD, et al. AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma. Mediastinum. 2026;10:AB008-AB008. doi:10.21037/med-26-ab008
BibTeX
@article{Remon2026,
author = {Remon, Jordi and Bironzo, Paolo and Girard, Nicolas and Bigay-Game, Laurence and Juan-Vidal, Oscar and Castro, Javier de and Reguart, Noemí and Greillier, Laurent and Cousin, Sophie and Dansin, Eric and Majem, Margarita and Bernabé, Reyes and Martinez, Joaquin Mosquera and Díaz, Marta and Meya, Alba and Alcalá-López, Daniel and García-Sanz, Alicia and Righi, Luisella and Novello, Silvia and Besse, Benjamin},
title = {AB008. Final analysis from PECATI phase 2 trial: lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma},
journal = {Mediastinum},
year = {2026},
volume = {10},
pages = {AB008--AB008},
doi = {10.21037/med-26-ab008}
}
EUVIMED